ArticleClinical Medicine Insights. Oncology2012
Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab.
Article in Clinical Medicine Insights. Oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Efficacy of Antiresorptive Drugs on Bone Mineral Density in Post-Menopausal Women With Early Breast Cancer Receiving Adjuvant Aromatase Inhibitors: A Systematic Review of Randomized Controlled Trials.Frontiers in oncology · 2021Pooled it
- Guidelines for the management of osteoporosis and fragility fractures.Internal and emergency medicine · 2019Guideline
- Lamina dura thickening in patients on antiresorptive therapy as a radiographic risk indicator of medication-related osteonecrosis of the jaw: a retrospective longitudinal cohort study.Dento maxillo facial radiology · 2026Article
- Case Study on the Use of Real-World Evidence in a Feasibility Assessment of a Randomized Controlled Trial Design to Support the Fulfillment of Pediatric Requirements with the FDA and EMA.Therapeutic innovation & regulatory science · 2026Article
- The Pathogenetic Role of RANK/RANKL/OPG Signaling in Osteoarthritis and Related Targeted Therapies.Biomedicines · 2024Review
- Clinical practice guidelines for full-cycle standardized management of bone health in breast cancer patients.Cancer innovation · 2024Article
- RANKL Blockade Reduces Cachexia and Bone Loss Induced by Non-Metastatic Ovarian Cancer in Mice.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2022Article
- Cancer Treatment-Induced Bone Loss: Role of Denosumab in Non-Metastatic Breast Cancer.Breast cancer (Dove Medical Press) · 2022Review
- Estrogen activates pyruvate kinase M2 and increases the growth of TSC2-deficient cells.PloS one · 2020Article
- Clinical and translational pharmacology of drugs for the prevention and treatment of bone metastases and cancer-induced bone loss.British journal of clinical pharmacology · 2019Review
- The skeletal impact of cancer therapies.British journal of clinical pharmacology · 2019Review
- Cancer Treatment and Bone Health.Calcified tissue international · 2018Review
- The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation.Oncotarget · 2017Review
- Assessment of off-label use of denosumab 60 mg injection during the early postmarketing period using health insurance claims data.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2016Article
- The best of both worlds - managing the cancer, saving the bone.Nature reviews. Endocrinology · 2016Review
- Adjuvant Endocrine Therapy and Bone Health in Breast Cancer.Current osteoporosis reports · 2015Review
- Antiresorptive therapy in the management of cancer treatment-induced bone loss.Current osteoporosis reports · 2015Review
- Skeletal manifestations of treatment of breast cancer.Current osteoporosis reports · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hormone ablation therapy (HALT) for breast or prostate cancer accelerates the development of osteoporosis in both men and women by causing estrogen deficiency, which increases the risk for fracture by promoting bone resorption mediated by osteoclasts. Denosumab, a fully human monoclonal antibody that inhibits osteoclast formation and function, increases bone mass in patients undergoing hormone ablation therapy. In the HALT study of 1,468 men with prostate cancer on androgen-deprivation therapy, denosumab significantly reduced the risk of new vertebral fractures, increased bone mineral density (BMD), and reduced markers of bone turnover. In a study of 252 women with breast cancer undergoing adjuvant aromatase inhibitor (AI) therapy, denosumab increased BMD at 12 and 24 months, overall and in all patient subgroups. The overall rates of adverse events were similar to placebo. Clinicians should consider fracture risk assessment and therapies such as denosumab to increase bone mass in patients on hormone ablation therapy who are at high risk for fracture.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.